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Background: In 1992 France set up a national cystic fibrosis observatory (Observatoire national de la mucoviscidose, ONM) to monitor the
state of health of patients on an annual basis. Using the ONM data, this study estimates the main indicators for life expectancy and assesses
the total number of cystic fibrosis patients.
Methods: The data for the years 1994 to 2003 are divided into 3-year periods. Life tables are drawn up for these periods, from which mean
and median lengths of life are determined. Using the most recent life table, the number of births in 2003 and the incidence of the disease, the
total population of patients can be estimated, assuming a stationary population.
Results: In 2001–2003, life expectancy at birth of patients registered with the ONM was 39.1 years and median length of life was 36.4 years.
These results, substantially better than those of 1994–1996, are linked to improved conditions of patient inclusion in the ONM database, to
improvements in their healthcare, but also to the limitations of the life tables. Based on the 2003 data, the total theoretical number of patients
is 6490, and coverage by the ONM database is thus 63.2%.
Conclusions: These provisional results demonstrate the need to convert the ONM observatory into a registry providing exhaustive coverage
of all patients.
© 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Mortality; Life expectancy; Stationary population; Database; Observatory1. Introduction
In most European countries as well as in North America,
cystic fibrosis patients are living significantly longer thanks
to improved disease management. Whereas only 20 years
ago cystic fibrosis was essentially a paediatric problem,
nowadays a steadily growing number of those affected are
adults [1–3].
Despite the high incidence of this disease, estimated at 1
in 4600 births [4], France has only recently set up☆ Grant support: From the association Vaincre la Mucoviscidose (Cystic
Fibrosis Association) Paris.
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1569-1993/$ - see front matter © 2006 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2006.07.001epidemiological monitoring of cystic fibrosis and organized
specific healthcare structures. Two important decisions have
been taken in this area however:
– Firstly, the creation in 1992 of a national cystic fibrosis
observatory (Observatoire national de la mucoviscidose,
ONM), initiated by the cystic fibrosis association, Vaincre
la Mucoviscidose. Basically, the ONM's objectives are to
improve knowledge of patients' medical and social
characteristics, to measure the impact of treatment
methods, to assess the socioeconomic cost of the disease,
and to supply patients, their relatives and partner
institutions with relevant information. The ONM works
in association with treatment centres specialized in the
management and follow-up of patients with cysticed by Elsevier B.V. All rights reserved.
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la Mucoviscidose association to take part in an annual
collection of epidemiological data organized by the
ONM. Since 1998, the ONM has been managed by the
Institut national d'études démographiques (INED), a
research institute which has been performing the ONM
surveys and analysing the data obtained since 1999.
– Secondly, the decision by the Ministry of Health in
October 2001 to introduce systematic neonatal screening
for cystic fibrosis on a national scale [5]. This decision
was accompanied by a procedure for recognition of
existing treatment centres as cystic fibrosis specialist
resource centres (Centre de ressources et de compétences
de la mucoviscidose, CRCM) [6]. Universal screening of
newborn babies was introduced in France in 2003 and the
CRCMs are building up a network to structure and
coordinate the care offered to patients, be they newborns
detected by screening or patients diagnosed from
symptoms occurring after birth. This national screening
programme appears to confirm, for the moment, an
incidence of the disease of 1 in 4600 births [7].
As the ONM is quite recent, mortality data had only been
partially analysed until now [8,9]. In this article we will
make a demographic analysis of the mortality of patients
monitored by the observatory database and on that basis,
estimate the total population of cystic fibrosis (CF) patients
in France. Measuring mortality levels, like the total number
of patients, may shed light on ways to improve the
epidemiological observation tool currently available.
2. Materials and methods
2.1. Data collection
Data are collected via questionnaires sent once a year to
the healthcare centres cooperating with the ONM in
mainland France and Réunion Island. The information
collected relates to the year just ended and concerns patients'
identities, diagnostic data, demographic events occurring
during the year, the method of medical follow-up, details of
therapeutic management, anthropometric, spirometric and
bacteriological parameters and some social data. For each
annual survey, each participating centre reports on the
patients seen at least once in the year. These patients may
have already been seen by the centre the previous year or
may have come for the first time during the year in question,
either as new patients or following a transfer from another
centre (these transfers are declared by clinicians for 2% of
patients, and include transfers from paediatric centres to
centres for adults). The reports submitted to the ONM by the
centres concern:
– firstly, patients who have been clinically diagnosed with
cystic fibrosis: the symptoms suggesting the disease,
occurring in isolation or in association, are mainlybronchopulmonary and/or chronic ENT symptoms, exo-
crine pancreatic insufficiency, growth retardation and
obstructive azoospermia [10,11];
– secondly, patients who do not necessarily exhibit the
phenotypical signs of the disease: they may be newborn
infants whose neonatal screening test was positive or
subjects with a family history of the disease.
In all cases, the diagnosis of cystic fibrosis is confirmed
by the sweat test (a concentration of chlorine in sweat above
60 mmol/l) and by detection of mutations of the CFTR gene.
The data examined in this article concern the deaths of
patients who were included in the ONM database from 1994
(the date from which more than 70% of the centres in France
contributed to the ONM) to 2003 (latest year for which
survey information is available); the data from 1994 to 1998
are aggregate data supplied by the previous ONM manager,
those from 1999 to 2003 are data on individuals collected
directly by INED.
2.2. Analysis of mortality
The intensity of mortality was calculated using crude
rates, measured as the ratio of the number of deaths to
the mean population (the arithmetic mean of initial and
final populations of each of the periods considered).
These rates fluctuate substantially from year to year due
to the small population size. To attenuate these fluctua-
tions, the rates – although still expressing the mean
annual numbers of events per 1000 patients – were
established for periods comprising 3 consecutive years:
1994–1996, 1995–1997, 1996–1998, 1997–1999, 1998–
2000, 1999–2001, 2000–2002, 2001–2003.
Mortality timing was measured by constructing abridged
period life tables for each of the eight 3-year periods. These
life tables give the following information:
– The number of deaths occurring between birthdays x and
x+5, written as: d(x, x+5).
– Five-year probabilities of dying, written as: 5qx which
correspond to the probability of dying between birthday x
and x+5. These probabilities were deduced from the
various age-specific rates (5-year rates, written as: 5mx)
using the following equation: 5qx=10×5mx/(2+5×5mx).
– The number of survivors at age x, written as: Sx. Hence:
Sx+5=Sx−d(x, x+5)=Sx×(1− 5qx).
– Life expectancy at age x, shown as: ex, where ex=2.5
+(5×(Sx+5+Sx+10+…)/Sx). Considering the age reached
by the last survivors, the maximum length of life for the
study population was fixed at 80 years. For several 3-year
periods, no death was actually observed after any
patient's fiftieth birthday. In order to close the life tables,
it was therefore necessary to work out a method for
eliminating survivors in the 50- to 80-year-old age group.
We opted arbitrarily for a regular extinction method,
assuming that the intensity of mortality was likely to
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that these deaths occurred in the middle of the 3-year
period.
Thus constructed, the period life tables describe for each
3-year period what would happen to a synthetic cohort of
newborn infants (arbitrarily limited to 1000 patients) who
experience, as they get older, the mortality conditions of the
period, and assuming zero migration (deaths of dropout
patients are not taken into account here). The probability
distribution is expressed in each life table as life expectancy
at birth (indicator expressing the average number of years
that a newborn exposed during his or her life to the risks of
dying calculated for the 3-year period considered might
expect to live), and median length of life (indicating the age
that a newborn of the period theoretically has a 50% chance
of exceeding) (Table 1, mortality 2001–2003).
Describing mortality conditions when there is migration
of any kind involves taking dropouts into account. The latter
have been correctly identified in the ONM database since
1999, the date from which individual-level data have been
available to permit statistical monitoring of all patients
included at least once in the database. On this basis, we
consider that dropouts in a year n are those who were
reported by a centre in year n−1, still alive on 31 December
of year n−1 and not seen again, or not declared by any
participating centre in any later year. To take account of
dropouts during each of the 3-year periods, counting from
1999 to 2001, the initial probabilities of dying are adjusted
by determining the ratio of the number of deaths d(x, x+5) to
the exposed population minus half the number of dropouts
between birthdays x and x+5.Table 1
Abridged life table
ONM
population,
2003
Mortality, 2001–2003 Stationary
population, 2003
Age n d(x, x+5) 5qx Sx ex 5px P(x, x+4)
0–4 687 1.00 0.0085 1000 39.1 0.996 827
5–9 654 3.00 0.0232 991 34.4 0.980 813
10–14 762 6.67 0.0431 968 30.2 0.948 787
15–19 681 10.33 0.0825 927 26.4 0.889 738
20–24 507 14.00 0.1456 850 23.6 0.789 655
25–29 360 11.00 0.1643 727 22.1 0.667 554
30–34 210 4.67 0.1256 607 21.0 0.569 472
35–39 120 3.67 0.2002 531 18.6 0.477 396
40–44 40 1.33 0.1554 422 17.8 0.390 324
45–49 38 0.67 0.1243 358 15.5 0.336 279
50–54 11 0.67 0.3137 313 12.4 0.265 220
55–59 12 0.33 0.1426 216 11.9 0.201 167
60–64 7 0.67 0.4511 185 8.4 0.142 118
65–69 10 0.33 0.2254 99 8.6 0.088 73
70–74 4 3.50 0.4375 77 5.3 0.060 50
75–79 1 4.50 1.000 43 2.5 0.022 18
80–84 0 0 0 0
Values in italics are estimations based on an arbitrary extinction method.2.3. Estimating the total population of patients and its age
structure in a stationary population
To estimate the population of patients, we adopt a
stationarity model which serves solely to give a highly
theoretical reference situation. We must make three assump-
tions for this purpose:
– a constant annual number of births (an assumption which
holds true for France over the last 30 years). It is set at
761500, the number registered in 2003 in France [12];
– an incidence of cystic fibrosis at birth of 1 in 4600 (data
confirmed by the latest systematic neonatal screening
data). From these two parameters, we deduce an annual
number (written as N) of 166 newborn infants suffering
from cystic fibrosis;
– reference mortality as given by the 3-year life table for the
period 2001–2003, which reflects the most recent
situation of the ONM but which applies current mortality
to all cohorts, including the oldest.
With the numbers supplied by the reference life table, the
following values can be determined:
– The probabilities of survival between the ages x and x+5,
shown as: 5px. Hence: 5px=(Sx+Sx+5)/2×S0 where S0 is
the population of 1000 newborns given in the life table.
– The number of patients in the stationary population per
age group, shown as P(x, x+4). With the values accepted
previously, the equation, per 5-year age group, becomes:
P(x, x+4)= (5×N)×5px.
– The total size of the stationary population, shown as P.
This number is: P=N×e0 where e0 is the life expectancy
at birth given by the table (Table 1, stationary population
2003).
Under the stationarity assumption, the size of the
population considered is constant. Moreover, the age
structure of this population depends exclusively on the life
table associated with it and remains constant over time [13].
3. Results
3.1. Characteristics of the ONM population
Between 1994 and 1999, the number of healthcare centres
– i.e. separate hospital services – cooperating with the ONM
rose from 59 to 91. The progressive creation of the CRCMs
from 2000 to 2001 led to a grouping of certain services,
thereby reducing the number of centres from 91 to 82 in 2003
(Table 2).
During this period, thanks to the improved service
provided by the CRCMs, the number of patients treated in
these centres increased steadily, rising from 2168 to 4104,
with an average annual increase of 7.5%. The median age of
ONM patients increased by 3.0 years, and the proportion of
Table 2
Characteristics of the ONM population
Characteristics Years
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Centres (N) 59 67 69 72 71 91 87 83 83 82
Patients (N) 2168 2524 2777 2937 2811 3220 3388 3580 3928 4104
Median age of patients (years) 11.0 11.6 12.0 12.0 13.0 13.0 13.0 14.0 14.0 14.0
Adults≥18 (%) 23.9 27.2 29.4 30.1 33.1 32.8 34.5 35.5 37.1 37.9
Median age at diagnosis (months) 5.0 4.0 5.0 5.0 5.0 4.0 4.0 4.0 4.0 4.0
Genotype a
ΔF508/ΔF508 (%) 58.4 56.7 55.3 54.2 52.6
ΔF508/other (%) 33.0 34.4 35.0 35.8 37.1
Other/other (%) 8.7 9.0 9.7 9.9 10.3
Taking pancreatic enzymes (%) 92.3 91.3 91.0 91.4 91.0 89.4 88.1 88.2 87.0 87.0
Mean FEV1 (% of predicted) 68.2 68.8 68.1 69.2 69.0 68.0 68.5 69.1 69.8 69.4
S.D. FEV1 (% of predicted) 27.4 27.1 27.9 28.2 28.3 27.7 27.4 27.6 27.8 27.4
Deaths (N) 46 55 54 75 63 44 45 53 66 56
Median age at death (years) 14.5 18.9 20.0 17.0 22.0 20.5 22.0 23.0 21.0 22.0
a Data available only for years 1999 to 2003.
Fig. 1. Distribution of survivors according to age on birthdays. Periods of
1994–1996 and 2001–2003.
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patients in 1994 to 38% in 2003. This substantial increase is
doubtless the consequence of several factors, including the
ageing of the cystic fibrosis population combined with
improved disease management in the CRCMs for adults. The
age at diagnosis remained stable, with half of all patients
diagnosed before the age of around 4 months.
When the two mutations of the CFTR gene were
identified (around 82% of patients), the most frequently
observed genotype was ΔF508/ΔF508 (52.6% in 2003),
with genotypes ΔF508/other and other/other representing
respectively 37.1% and 10.3% in 2003. These frequencies
are quite similar to those observed in most European
countries.
In 1994, 92.3% of the ONM patients took pancreatic
enzymes. This proportion fell progressively to 87% in 2003.
The mean FEV1 appears to have remained quite stable
throughout the study period, varying between 68% of the
predicted value in 1999 and almost 70% in 2002.
In this type of rare disease, the number of deaths is
naturally low. In the ONM, it rose from 46 in 1994 to 56 in
2003 but with major fluctuations from year to year, with a
maximum of 75 in 1997. The median age at death, between
14.5 years in 1994 and 22.0 years in 2003, also fluctuates
considerably, as it is dependent on the age structure of the
study population and on its variations over the years. It is no
more than indicative.
3.2. Characteristics of mortality
3.2.1. Intensity and timing of mortality (Table 3)
The crude death rate, which stood at 21.6‰ in 1994–
1996, peaked at 23.9‰ in 1995–1997 then fell steadily to
15.8‰ in 2001–2003. Death rates by age group follow this
overall trend, falling from 7.0‰ to 1.7‰ in the 0–4 age
group and from 79.1‰ to 27.0‰ in the 45–49 age group
between 1994–1996 and 2001–2003.The indicators taken from the life tables, independent of
the study population age structures, summarise mortality
conditions for patients included in the ONM database more
accurately than the above figures. Life expectancy at birth
calculated for the period 1994–1996 is 30.4 years, and for
2001–2003 it is 39.1 years; life expectancy at age 20 (the
mean number of years of life remaining for a patient who has
survived to his or her twentieth birthday) is 16.7 years with
the 1994–1996 data and reaches 23.6 years with the 2001–
2003 data.
The distribution of survivors at the different birthdays and
the associated indicators of median length of life clearly
illustrate this change in the timing of mortality observed
between the two periods at each end of the study (Fig. 1): a
substantial difference is observed between the two survival
profiles from the fifteenth birthday and this difference is then
maintained. In the mortality conditions of the period 1994–
1996, a newborn would have a one in two chance of
exceeding 28.1 years of age, while in the mortality
conditions of the period 2001–2003, a newborn would
have a one in two chance of exceeding 36.4 years of age.
Table 3
Mortality characteristics of patients in the ONM database
Periods Mortality indicators
Crude
death
rates (‰)
Life
expectancy
at birth (years)
Life
expectancy
at age 20 (years)
Median
length of life
(years)
1994–1996 21.6 30.4 16.7 28.1
1995–1997 23.9 30.9 18.1 27.8
1996–1998 23.4 32.0 18.5 28.1
1997–1999 21.3 34.0 20.4 29.6
1998–2000 16.8 37.1 21.6 32.2
1999–2001 14.7 39.0 23.0 35.7
2000–2002 15.8 38.0 22.4 35.6
2001–2003 15.8 39.1 23.6 36.4
Table 4
Mortality characteristics of patients in the ONM database corrected for
dropouts
Periods Mortality indicators
Crude
death
rates (‰)
Life
expectancy
at birth (years)
Life
expectancy
at age 20 (years)
Median
length of life
(years)
1999–2001 14.9 38.6 22.7 35.4
2000–2002 16.0 37.7 22.1 35.4
2001–2003 16.0 38.7 23.2 36.1
183G. Bellis et al. / Journal of Cystic Fibrosis 6 (2007) 179–186Throughout the study period, most deaths (66.2%) were
due to a respiratory cause; other correctly recorded main
causes were cardiac (4.3%) and hepatic (1.3%) causes,
trauma (1%) and suicide (1%).1 When the primary cause is
respiratory, quite frequently organ transplantation is a
particular circumstance of death. During the period 2001–
2003 for example, this was observed in 16% of cases.
3.2.2. Data corrected for dropouts
The number of dropouts over the 3-year period 1999–
2001 was 251, i.e. 7.8% of the average reference population;
the numbers were 222 for 2000–2002 (6.3% of the
population) and 321 for 2001–2003 (8.7% of the popula-
tion). For each of these three periods, nearly 80% of dropouts
were under 25, the majority of them being in the 15–19 age
group. Analysis of the FEV1 of all these dropouts shows
that:
– this criterion is only available for 68% of them, compared
with 72% of the full set of ONM patients over the same
period (1999–2003);
– the means of the predicted value are 64.4 (years 1999–
2001), 68.3 (2000–2002) and 76.2 (2001–2003); only
this latter value is significantly higher than the mean
observed for the entire ONM at the same period
(Student's test: p<0.001); the health status of dropouts,
on the basis of this criterion, does not appear to be very
different from that of ONM patients overall.
Taking dropouts into account only slightly modifies the
mortality indicators shown above (Table 3). For 2001–2003
for example, the crude death rate, which was 15.8‰, rises to
16.0‰ after correcting for dropouts (Table 4). Likewise, life
expectancy at birth falls from 39.1 to 38.7 years and median
length of life from 36.4 to 36.1 years.1 For all other reported causes, the proportion was below 1%. All these
causes combined represent 17.2% of causes of death and 9.2% are non-
documented causes.3.3. Estimating the total theoretical population of those
affected
Assuming stationarity and taking life expectancy at birth
to be 39.1 years, the theoretical total population of CF
patients in France is an estimated 6490. As the number of
patients actually observed by the ONM in 2003 was 4104,
coverage by the observation tool is therefore 63.2%. The
adjustment resulting from the inclusion of dropouts is minor:
with a life expectancy of 38.7 years, the theoretical total
population would be 6420 patients and coverage 63.9%.
Differences between the size of the observed population
and that of the stationary reference population deduced
from the latest life table vary substantially depending on age
(Fig. 2). At age 10–14, the difference between the two
series is very small, with a coverage rate of 96.8%; at age
0–4, the difference is quite large (687 patients observed
versus 827 patients theoretically expected) and ONM
coverage is 83.1%; at age 5–9, this difference increases
slightly, and coverage is now only 80.4%. It is in the older
age ranges (age 30 and above) that the differences in
numbers become more pronounced. This is to be expected
since the stationary model severely overestimates the
survival of the oldest cohorts: at age 35–39, 120 patients
are observed versus 396 predicted by the model, and
likewise for the 50–54 age group, with 11 patients observed
versus a predicted figure of 220.Fig. 2. Observed and estimated population by age. Year 2003; incidence at
birth: 1 in 4600.
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Based on this demographic analysis, we can establish that
over the recent period (2001–2003), life expectancy at birth
of patients included in the database is around 39 years and
median length of life is slightly above 36 years. However,
despite the increasing number of patients included in the
ONM database each year, the quality of the observation tool
seems to be inadequate. Indeed, if incidence is 1 in 4600
births, then the 4104 patients recorded in 2003 represent only
about 63% of the total population of CF patients estimated
for a stationary population.
The increase in the life expectancy indicators between the
two periods at each end of the study (+8.7 years life
expectancy at birth and +8.3 years median length of life in
7 years), as well as their levels for the most recent period,
should be interpreted with caution and doubtless over-
estimate the real situation. This can be explained by a
number of factors:
– the data on which this analysis is based are not
exhaustive. The surveys carried out each year by the
ONM do not reach all patients since they only concern
those consulting one of the healthcare centres cooperating
with the ONM. As Fig. 2 illustrates, a considerable
number of patients fall through the net, perhaps because
they are treated outside the centres, or because they have
not yet been diagnosed or because they suffer from a
milder form of cystic fibrosis that does not require an
annual medical check-up. As regards mortality data,
information concerning patients who die outside the
range of participating centres is therefore missing, as well
as deaths in the first months of life when diagnosis has not
yet been confirmed. Regarding this last category of
deaths, the generalisation of systematic neonatal screen-
ing is still too recent for the deficits of the youngest
patients to have been totally absorbed. Comparison of
annual deaths observed by the ONM with those recorded
by the Institut national de la santé et de la recherche
médicale (INSERM) in the national database of deaths by
cause [14] indicates that the level of under-reporting of
deaths in the ONM is 14% for all ages. Under-reporting
varies substantially between ages, but is most evident in
the extreme age groups of 0–9 years on the one hand, and
above 35 on the other (deficit of at least 30% on average
compared with INSERM deaths). For certain years and
certain age groups, ONM deaths are nonetheless over-
reported with respect to INSERM deaths. These compar-
isons confirm the non-exhaustive nature of the OMS
database, though the reliability of INSERM data on death
by cause may also be uncertain.
– the gradual improvement in the level of ONM coverage
over the years has produced a positive balance of
observation entries with respect to dropouts, with a
particular age structure. Generally speaking, the surpluses
are found in the youngest age groups with the least risk ofdying (in particular the group of 0–4 year olds) and
deficits concern the adult age groups which, on the
contrary, have the highest risk of dying. Overall, this
balance therefore weighs in favour of delayed mortality
timing. Over the last three periods of the study, the extent
of this phenomenon was only very partially corrected by
taking dropouts into account. Moreover, analysis of the
proportion of patients taking pancreatic extracts (Table 2)
appears to indicate a progressive increase, throughout the
study period, of patients with a mild form of cystic
fibrosis in terms of clinical symptoms. This tendency also
appears to be confirmed by the decrease, from 1999 to
2003, in the proportion of patients with a homozygotic
ΔF508 genotype, which again weighs in favour of
reduced mortality. This reduced mortality may be
attributable not to an actual improvement in health but
rather to a progressive change in the composition of the
study population.
– we introduced a certain amount of arbitrariness into the
calculations of mortality at advanced ages (age 50 and
above) in view of our chosen level of longevity; this is
due to the inclusion of a patient aged 75 in the ONM
database in 2000. Increasing longevity does not affect the
values for median length of life but does modify the
values for mean length of life (the maximum increase
being 0.9 years when longevity is increased from 70 to
80 years).
Despite earlier reservations, cross-sectional analysis of
mortality does have the basic advantage of producing
various indicators which summarise the fatal events that
affected the study population each year (or over a given
period). However, life expectancy at birth and median
length of life simply reflect mortality conditions at a given
moment in time. One must beware, therefore, of thinking
that the newborn infants in 2001–2003 will in fact survive
on average for 39.1 years. This mean length of life will only
be observed if the mortality conditions of the period 2001–
2003 are maintained over the long term. The fate of the
cohorts of patients born during the years 2001–2003 will
very probably differ (as progress is made in treating the
disease) from that of the synthetic cohort and from the
instantaneous distribution of survivors that we constructed
to measure the level of mortality for this period. Consider-
ing the low numbers observed and the limitations
mentioned earlier, it would seem preferable to use the
indicator of probable length of life (or median length of life)
rather than that of mean length of life to compare France
with other countries, although the methods used to measure
mortality timing are sometimes very different [15,16]. The
following median lengths of life are thus obtained for some
of the countries that have cystic fibrosis databases: the
United States (1999) 29.1 years [17], Canada (1985–1989)
27.8 years for women and 36.7 years for men [18], Great
Britain (estimates for the present period based on 1994 data)
about 30 years for women and 31 years for men [19],
185G. Bellis et al. / Journal of Cystic Fibrosis 6 (2007) 179–186Germany (1999) 31.6 years [20]. The former European
registry for cystic fibrosis, which grouped together
Germany, Belgium, Denmark, France, Great Britain, Ire-
land, the Netherlands and Sweden gave (for 1998)
32.0 years for median length of life [21]. An exploratory
standardised study on mortality and related indicators
undertaken by INED using data from France, Germany,
Denmark, Italy and the United States has been very useful
for comparing the differences in levels between these
countries [22,23].
Estimating the total population of patients under the
assumption of stationarity is only indicative, as no real
population is strictly stationary. The stationary population
must be considered as a reference population that can be
used to assess, by comparison, certain concrete situations
(as shown in Fig. 2). The calculations indicate that the
ONM level of coverage may vary substantially from one
age group to another. Under the stationarity assumption,
we may consider these differences to be related to
characteristics associated with the patients' age. Before
10–14 years, we observe a delay in diagnosis (in 2003, the
median age at diagnosis was 4.0 months and the mean age,
37.7 months) and therefore a delay in entry into the ONM
database; this delay will however gradually be absorbed by
the implementation of neonatal screening. After 10–
14 years, one can consider that the mortality of previous
cohorts2, much higher in reality than that described by the
reference life table (2001–2003) – especially for advanced
ages – partly explains the divergence between observed
and predicted numbers. But there is also probably a large
number of adult patients with mild forms of cystic fibrosis,
who do not pass through the care centres. For their part,
clinicians consider the large drop in levels of ONM
coverage after age 15 to be rather unlikely and, conse-
quently, also the estimate of the total adult population with
the disease.
To conclude, it would seem essential to develop the
observation tool currently available in France and to move
on from a database, where registration of patients is
incomplete, to a registry, in which inclusion and follow-up
must be exhaustive. This should be possible, since newborn
infants with the disease screened since 2002–2003 in France
must be examined by a CRCM at least once a year. The
inclusion of patients in this registry from birth will ensure
reliable monitoring of their health status over the years and
guarantee the robustness of a certain number of epidemio-
logical indicators, notably that of mortality.
Achieving this objective calls for the creation of a multi-
source structure to collect data on each patient. In addition to
the standard healthcare structures, represented by the
CRCMs, the following bodies could be involved:
– the organisation in charge of neonatal cystic fibrosis
screening (AFDPHE),2 Who were born in 1987 or before as they were at least fifteen in 2002.– centres treating male sterility,
– the various state health insurance bodies, since all French
people are covered by health insurance, whatever their
economic status. They would provide a source of
information on patients declared as having a long-term
illness.
Only through concerted action of this kind will we
develop our knowledge of cystic fibrosis in France.
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